Amyloidosis is characterized by accumulation of amorphous material in various organs and tissues due to a variety of inflammatory, immune, infectious, and hereditary diseases. Our transplantation team has performed 1486 renal transplantations since 1975. The last 1165 transplantations were performed at Baskent University Hospital between 1985 and July 2004. Of these, 958 (82.3%) were from living donors and 207 (17.7%) were from cadaveric donors. There were 32 recipients (28 men and 4 women; mean age, 31.4 ± 1.7 years; range, 21-48 years) with amyloidosis. Twenty-eight (87.5%) of these recipients had received grafts from living donors, and 4 (12.5%) had received grafts from cadaveric donors. Amyloidosis was secondary to familial Mediterranean fever in 22 (68.7%) cases and rheumatoid arthritis in 1 (3.1%) case. The remaining 9 (28.1%) cases had primary amyloidosis. Mean follow-up was 51.2 ± 5.7 months (range, 2-124 months). Mean HLA mismatch rate was 2.2 ± 1. Twenty-six (81.2%) of these patients are currently alive with functioning grafts, with a mean serum creatinine value of 2.1 ± 1.5 ng/dL. The 1- and 5-year patient and graft survival rates were 90.6% and 84.3%, and 81.2% and 68.7%, respectively. Patients with amyloidosis can safely undergo kidney transplantation and expect outcomes similar to individuals receiving transplantation for other reasons.